Shalabh Gupta

Shalabh Gupta, MD, founded Unicycive and has served as Chief Executive Officer, President, and director since August 2016. Previously, Dr. Gupta served in various other roles, including founder and Chief Executive Officer of Biocycive Inc.; a commercial strategist at Genentech, Inc.; equity researcher covering US pharmaceutical companies at UBS Investment Bank; and as an equity researcher covering biotechnology companies at Rodman & Renshaw (currently HC Wainwright). Dr. Gupta previously served as a medical advisor to Synageva BioPharma Corporation and as an advisor to New York University (NYU) Langone Medical Center’s Office of Technology Transfer. Dr. Gupta is also the founder and Chief Executive Officer of Globavir, a company with a diagnostic platform technology licensed from Stanford University, which partnered with Bio-Rad (NASDAQ: BIO) in 2016 and later with Cepheid (now part of Danaher Corporation, NYSE: DHR). Bio-Rad currently sells this technology as part of their RUO (Research Use Only) kits, and Danaher is advancing diagnostic technology through the regulatory approval process worldwide.

Dr. Gupta is an advisor to the UCSF Innovation Center, a role he has held since 2020. Since 2012, Dr. Gupta has also been an advisor to SPARK, Stanford University School of Medicine. Dr. Gupta previously served on the board of directors for the Beall Center for Innovation and Entrepreneurship at the University of California Irvine, Paul Merage School of Business.

Before his roles in business and finance, Dr. Gupta was an attending physician at New York University (“NYU”) Medical Center and a clinical faculty member at the NYU School of Medicine. Dr. Gupta was a board-certified physician currently licensed by the California State Medical Board.

Dr. Gupta completed his internship in Internal Medicine, medical residency in Physical Medicine and Rehabilitation, and research fellowship in Cardiopulmonary Rehabilitation at NYU School of Medicine. Dr. Gupta received his MPA in Health Care Finance and Management from NYU’s Robert F. Wagner Graduate School of Public Service and his MD from Jawaharlal Institute of Postgraduate Medical Education & Research, India. Dr. Gupta has been in several leadership roles throughout his academic and professional career. He was elected president of the Resident Physicians Council during his residency training, representing approximately 1,500 resident physicians in physical medicine and rehabilitation across the US. He also also served on the Board of Directors at the Wagner Alumni Association.

Shalabh Gupta is the Founder & CEO at Unicycive Therapeutics, based in United States, North America. With a background in Biotechnology, Shalabh Gupta has a rich history of leadership and innovation. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.